RichardThomasMaziarzMD

Oncology • Portland, OR

Hematologic Oncology

Medical Director, Adult Stem Cell Transplant Program; Professor, Oregon Health & Science University

Join to view full profile

Dr. Maziarz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Maziarz's full profile

Already have an account?

Office
3181 Sw Sam Jackson Park Rd
Mail Code Uhn73c
Portland, OR 97239
Phone+1 503-494-4606
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1987
Harvard Medical SchoolClass of 1979

Certifications & Licensure

HI State Medical License 2024 - 2026
OR State Medical License 1992 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Portland Monthly Magazine Castle Connolly, 2011
Join now to see all

Clinical Trials

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 3
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Start of enrollment: 2005 Mar 01
Completed
Phase 2
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 1, Phase 2
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML Start of enrollment: 2003 May 01
Terminated
Phase 2
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia Start of enrollment: 2008 Jul 01
Completed
Phase 1
Fosaprepitant for Breakthrough Chemotherapy Induced Nausea and Vomiting Start of enrollment: 2009 Dec 01
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Start of enrollment: 2013 Mar 01
Active, not recruiting
Phase 1, Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies Start of enrollment: 2020 Jul 08
Active, not recruiting
Phase 3
Roles: Principal Investigator, Contact
DALY 2.0 USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients.
Hong De Sa, Richard T Maziarz, Arpita P Gandhi> ;Expert Opinion on Biological Therapy. 2024 Mar 1
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1...
Wael Saber, Aasthaa Bansal, Lily Li, Bart L Scott, Lindsey R Sangaralingham, Viengneesee Thao, Joshua A Roth, Winona Wright, Lotte M G Steuten, Joseph A Pidala, Asmita...> ;JCO Oncology Practice. 2024 Apr 1
1 citations
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Le...> ;Bone Marrow Transplantation. 2023 Dec 1
1 citations
Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis fro...
Navneet S Majhail, Beckley Miller, Rebecca Dean, Rocio Manghani, Heayoung Shin, Smitha Sivaraman, Richard T Maziarz> ;Transplantation and Cellular Therapy. 2023 Dec 1
2 citations
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
Ahmed, N., Wesson, W., Mushtaq, M., Porter, D., Nasta, S., Brower, J., Bachanova, V., Hu, M., Nastoupil, L., Oluwole, O., Patel, V., Oliai, C., Riedell, P., Bishop, M....> ;Transplantation and Cellular Therapy. 2023 Jul 1
2 citations
Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.
Richard T Maziarz, Steven Devine, Louis P Garrison, Irene Agodoa, Jack Badaracco, Matthew Gitlin, Miguel-Angel Perales> ;Transplantation and Cellular Therapy. 2023 Oct 1
1 citations
A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
Titas Banerjee, Matthew Newman, Andy Chen, Richard T Maziarz, Levanto Schachter, Stephen E Spurgeon, Anusha Vallurupalli> ;Leukemia & Lymphoma. 2023 Jun 7
7 citations
Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques.
Helen L Wu, Kathleen Busman-Sahay, Whitney C Weber, Courtney M Waytashek, Carla D Boyle, Katherine B Bateman, Jason S Reed, Joseph M Hwang, Christine Shriver-Munsch, T...> ;Immunity. 2023 Jul 11
22 citations
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
Curtis A Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F Newell, Brandon Hayes-Lattin, Richard T Maziarz, Jessica Leonard, Daniel Bottomly, Shannon McW...> ;Blood Advances. 2023 May 9
2 citations
A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.
Joseph S Bubalo, Jennifer L Radke, Kenneth G Bensch, Andy I Chen, Shikha Misra, Richard T Maziarz> ;Journal of Oncology Pharmacy Practice. 2024 Mar 1
Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic...
Georgeann Booth, Yun Yu, Rogelyn P Harlan, Carol E Jacoby, Kaitlyn M Tomic, Susan E Slater, Bryon E Allen, Elizabeth M Berklich, Rebekah J Knight, Julieann Dela Cruz, ...> ;Cytotherapy. 2023 Apr 1
5 citations
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
Rezvani, A. R., Chenyu Lin, Gautam Sajeev, Patrick J Stiff, Claudio G Brunstein, Corey Cutler, Guillermo Sanz, Caroline A Lindemans, Andrew R Rezvani, Rabi Hanna, Lian...> ;Transplantation and Cellular Therapy. 2023 Jan 1
A new beginning: can omidubicel emerge as the next, viable alternative donor source?
Arpita P Gandhi, Laura F Newell, Richard T Maziarz> ;Therapeutic Advances in Hematology. 2023 Jan 1
1 citations
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL.
Richard T Maziarz, Jordan Gauthier> ;Nature Reviews. Clinical Oncology. 2023 Jan 1
Serial Transthoracic Ultrasonography Studies in Hematopoietic Cell Transplant Patients: A Tool for Early Lung Pathology Detection.
Meihua Zhu, Cynthia R Gregory, Brandon Hayes-Lattin, Carol Jacoby, Xijun Zhang, Amber Halse, Fen Wang, Kenton W Gregory, Richard T Maziarz> ;Ultrasound in Medicine & Biology. 2023 Jan 1
31 citations
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Ce...
Riedell, P., Hwang, W., Nastoupil, L., Pennisi, M., McGuirk, J., Maziarz, R., Bachanova, V., Oluwole, O., Brower, J., Flores, O., Ahmed, N., Schachter, L., Bharucha, K...> ;Transplantation and Cellular Therapy. 2022 Oct 1
9 citations
Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an...
Richard T Maziarz, Hongbo Yang, Qing Liu, Travis Wang, Jing Zhao, Stephen Lim, Soyon Lee, Anand Dalal, Vamsi Bollu> ;Leukemia & Lymphoma. 2022 Sep 1
1 citations
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Ulrich Jaeger, Constantine S Tam, Peter Borchmann, Joseph P McGuirk, Marianne Johansen, Edmund K Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R Foley, Ja...> ;Blood Advances. 2022 Aug 23
11 citations
Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery.
Richard T Maziarz, Amber Diaz, David B Miklos, Nirav N Shah> ;Transplantation and Cellular Therapy. 2022 Nov 1
26 citations
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Jordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, Joshua A Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A Chow, Ajay K Gopa...> ;Blood. 2022 Jun 30
4 citations
Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
Joshua A Hill, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Michael Boeckh, Richard T Maziarz> ;Transplantation and Cellular Therapy. 2022 Sep 1
25 citations
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
G Ghilardi, E A Chong, J Svoboda, P Wohlfarth, S D Nasta, S Williamson, J D Landsburg, J N Gerson, S K Barta, R Pajarillo, J Myers, A I Chen, L Schachter, R Yelton, H ...> ;Annals of Oncology. 2022 Sep 1
8 citations
Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.
Richard T Maziarz, Jie Zhang, Hongbo Yang, Xinglei Chai, Chengbo Yuan, Elisabeth Schwarz, Mihael Jakovac, Marcela Martinez-Prieto, Abhijit Agarwal, Evgeny Degtyarev, C...> ;Blood Advances. 2022 Apr 26
7 citations
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
Stephen J Schuster, Jie Zhang, Hongbo Yang, Abhijit Agarwal, Wenxi Tang, Marcela Martinez-Prieto, Vamsi Bollu, David Kuzan, Richard T Maziarz, Marie José Kersten> ;Leukemia & Lymphoma. 2022 Apr 1
1 citations
Post-allogeneic stem cell transplant- targeted maintenance therapy: updates and considerations for clinical practice.
Jonathan Cohen, Richard T Maziarz> ;Archives of Stem Cell and Therapy. 2022 Jan 1
Join now to see all

Abstracts/Posters

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
Richard T. Maziarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Monkey Model Offers Clues for Potential Widespread HIV Cure in PeopleMay 25th, 2023
Research Offers Clues for Potential Widespread HIV Cure in People: New Study Reveals First Details on How Stem Cell Transplantation Can Kill Virus That Causes AIDSMay 25th, 2023
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health EquityApril 25th, 2022
Join now to see all